Children with moderate/more extensive atopic dermatitis treated with ruxolitinib cream achieved significant disease control ...

In statements to the USA TODAY Network, both the University of Rochester Medical Center, or URMC, and Regeneron noted they ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the Most Undervalued Long Term Stocks to Buy According to Hedge Funds ...

Flattery has been an effective tool with the president. In addition to the concessions won by Cook and Apple, Jensen Huang, CEO of semiconductor company Nvidia, has lavished praise on Trump’s vision ...

Strand Therapeutics raised a $153 million Series B to develop programmable mRNA therapeutics and reshape how we treat disease ...

Strand Therapeutics announced on Thursday that it landed a $153 million Series B funding led by Kinnevik. The company’s ...

The close-knit South Shore village scored points for its strong public schools, quick commute to NYC and nearby beach access, ...

Regeneron Pharmaceuticals (($REGN)) announced an update on their ongoing clinical study. Regeneron Pharmaceuticals, in collaboration with Servier ...

Strand Therapeutics has raised $153 million in second-round financing that will be used to move its programmable mRNA ...

Intervention/Treatment: The trial tests Itepekimab, administered subcutaneously in high and low doses, alongside Mometasone furoate nasal spray. The purpose is to improve symptoms in patients with ...

Sanofi’s shift to immunology, AI-driven R&D, and strong pipeline offset risks from patent cliffs and legal issues. See why ...

No revenue reported as clinical programs remain in precommercial stages. Workforce and cost reductions are expected to extend cash runway into the fourth quarter of 2026. Adicet Bio (NASDAQ:ACET), a ...